Overview
RVMD market data
Price History
RVMD price chart · 1M
- O
- 221.32
- H
- 224.18
- L
- 216.27
- C
- 220.48
- Vol
- 123,159.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $221.32
- Previous Close
- $215.16
- Day High
- $224.18
- Day Low
- $216.27
- 52 Week High
- $224.18
- 52 Week Low
- $139.25
- 7 Day Return
- +4.07%
- 30 Day Return
- +19.93%
- 90 Day Return
- +39.91%
- 1 Year Return
- +56.86%
- Daily Notional Volume
- $27.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.95 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.41 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,833.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $35.42 – $220.34 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $43.2B · P/B 9.44 · P/S 3,733.66.
Company News
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock SurgesBenzinga · Aug 27, 2026, 5:13 PM
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer DrugBenzinga · Aug 27, 2026, 3:44 PM
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival ResultsBenzinga · Aug 27, 2026, 3:08 PM
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260Benzinga · Aug 27, 2026, 2:42 PM
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251Benzinga · Aug 27, 2026, 2:30 PM
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $225Benzinga · Aug 27, 2026, 1:25 PM
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239Benzinga · Aug 27, 2026, 1:02 PM
Top 3 Health Care Stocks That May Keep You Up At Night In Q3Benzinga · Aug 27, 2026, 12:46 PM
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320Benzinga · Aug 27, 2026, 12:43 PM
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $280Benzinga · Aug 27, 2026, 12:15 PM